Real-World Data Supports Medtronic's Next-Gen Insulin Pump

Data presented at the American Diabetes Association meeting shows that using the Medtronic MiniMed 780G insulin pump improves glycemic outcomes with less effort from patients.

Katie Pfaff

June 6, 2022

2 Min Read
Medtronic MiniMed 780G.png
Image courtesy of Medtronic

Real-world data from two recent studies point to the Medtronic MiniMed 780G maintaining a majority of time in glucose range, according to information shared over the weekend at the American Diabetes Association meeting.

Medtronic’s hybrid closed loop system achieved more than 70% time in range (TIR), and with less patient involvement. MiniMed 780G includes “meal detection technology” which continuously monitors and makes required adjustments to glucose in 5-minute intervals.

The real-world data from a pair of studies in Chile and Europe achieved results that suggest MiniMed 780G can improve outcomes and achieve consensus guideline recommendations for TIR. The European research also provided the first real world data with the Guardian 4 senor.

Medtronic MiniMed 780G data from European research

European participants older than 15 (4,786) had an overall TIR of 74.2% and those 15 years and younger (2,159) had an overall TIR of 70.2%. Overall TIR across all age groups (6,989) was 72.9%. Overnight TIR for same age groups were 80.5%, 80.6%, and 80.5%, respectively.

A secondary target – glucose management indicator (GMI) – was mostly below 7%: 6.98% overall, 7.04% in participants 15 and younger, and 6.95% in participants older than 15 years of age. Participants who used a setting of 2-hour active insulin time and a 100 mg/dL target glucose, reached the lowest (1.8%) amount of time below range and the highest (78.8%) TIR.

A smaller real-world European study looked at 674 participants who used MIniMed 780G and transitioned from Guardian 3 to Guardian 4. The change dropped the number of exits from 1.1 per week to 0.83 per week, respectively, suggesting patients could do fewer fingersticks while also managing glucose.

Medtronic MiniMed 780G data from Chile research

Additional study of 37 participants age 5- to 76-years-old across Chile with type 1 diabetes found that the TIR average was 78.4%. At the same time, 77% of participants reached the targets of TIR greater than 70% and GMI below 7%. Those who utilized recommended settings, reached 80.1% TIR, the lowest in the group.

Further, the TIR among seven users who switched from MiniMed 640G to MiniMed 780G jumped from 68.9% to 79.5%, and from 75.3% to 78.1% among 30 particopants who switched from MiniMed 670G to MiniMed 780G.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like